Related Experiment Video
Updated: Jun 25, 2026

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
Published on: April 15, 2014
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE
W A Roscoe1, M E Welsh, D E Carter
1Departments of Physiology and Pharmacology, and Diagnostic Imaging, University of Western Ontario, Ontario, Canada.
Abstract:
An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG ((35-55))) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls (p<0.001), with less demyelination (-37%) and cellular infiltration (-23%) in the spinal cord (p<0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1+/-6.1 v. 81.6+/-11.5, p<0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p<0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p>0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control (r=0.723, r=0.665) and treated (r=0.681, r=0.487) animals (all p<0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p<0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.
Insights
In acute experimental autoimmune encephalomyelitis (EAE), inhibiting vascular endothelial growth factor (VEGF) improved clinical outcomes and reduced demyelination. However, this treatment showed no benefit in chronic EAE, suggesting a critical role for VEGF in early disease stages.
Area of Science:
- Neuroimmunology
- Vascular Biology
- Experimental Pathology
Background:
- Increased vascular endothelial growth factor (VEGF) expression is linked to demyelinated lesions in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
- Vascular changes, particularly those involving VEGF, are implicated in the formation of central nervous system (CNS) plaques.
Purpose of the Study:
- To investigate vascular alterations in acute and chronic EAE in mice induced with myelin oligodendrocyte glycoprotein (MOG) peptide.
- To determine the functional role of VEGF in EAE by inhibiting VEGF receptor 2 (VEGFR2) using SU5416 (Semaxinib).
Main Methods:
- Induction of EAE in C57BL/6 mice using MOG (35-55) peptide.
- Treatment with SU5416 (VEGFR2 inhibitor) or vehicle during acute or chronic EAE phases.
- Assessment of clinical scores, spinal cord pathology (demyelination, cellular infiltration, laminin deposits), blood vessel density, and angiogenic gene expression.
Main Results:
- MOG induction caused demyelination, immune cell infiltration, laminin deposits, and axonal loss.
- In acute EAE, SU5416 treatment significantly improved clinical scores, reduced demyelination and cellular infiltration, and decreased blood vessel density and laminin abnormalities.
- VEGF expression positively correlated with clinical scores and pathology in acute EAE.
- SU5416 treatment during chronic EAE showed no significant improvement in clinical scores or pathology.
- Microarray analysis revealed increased expression of angiogenic RNA transcripts in acute EAE.
Conclusions:
- VEGF plays a critical role in the vascular pathology of acute EAE, and its inhibition can ameliorate disease.
- Vascular alterations, including increased VEGF and laminin deposits, are associated with CNS lesion formation in EAE.
- Targeting VEGF may be a viable therapeutic strategy for early-stage MS, but not for chronic disease stages.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis

